SG11201908326YA - Methods of treating neurodegenerative diseases - Google Patents
Methods of treating neurodegenerative diseasesInfo
- Publication number
- SG11201908326YA SG11201908326YA SG11201908326YA SG11201908326YA SG 11201908326Y A SG11201908326Y A SG 11201908326YA SG 11201908326Y A SG11201908326Y A SG 11201908326YA SG 11201908326Y A SG11201908326Y A SG 11201908326YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- genentech
- california
- pct
- san francisco
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) WIPO I PCT (51) International Patent Classification: C07K 16/18 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/US2018/024300 (22) International Filing Date: ill 1111u°11111VIIIVIIII o monii mina° oimIE (10) International Publication Number WO 2018/183175 Al (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/477,535 62/532,696 62/577,559 62/580,359 26 March 2018 (26.03.2018) English English 28 March 2017 (28.03.2017) US 14 July 2017 (14.07.2017) US 26 October 2017 (26.10.2017) US 01 November 2017 (01.11.2017) US (71) Applicant: GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, California 94080 (US). (72) Inventors: KERCHNER, Geoffrey; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). TENG, Edmond; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). (74) Agent: SCARR, Rebecca B. et al.; 500 W. Silver Spring Drive, Suite K-200, Glendale, Wisconsin 53217 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) N with sequence listing part of description (Rule 5.2(a)) 00 1-1 O C \" (57) : The invention provides methods of treating tauopathies with anti-Tau antibodies. (54) Title: METHODS OF TREATING NEURODEGENERATIVE DISEASES
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762477535P | 2017-03-28 | 2017-03-28 | |
US201762532696P | 2017-07-14 | 2017-07-14 | |
US201762577559P | 2017-10-26 | 2017-10-26 | |
US201762580359P | 2017-11-01 | 2017-11-01 | |
PCT/US2018/024300 WO2018183175A1 (en) | 2017-03-28 | 2018-03-26 | Methods of treating neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908326YA true SG11201908326YA (en) | 2019-10-30 |
Family
ID=62063590
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908326Y SG11201908326YA (en) | 2017-03-28 | 2018-03-26 | Methods of treating neurodegenerative diseases |
SG10201911225WA SG10201911225WA (en) | 2017-03-28 | 2018-03-26 | Methods of treating neurodegenerative diseases |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201911225WA SG10201911225WA (en) | 2017-03-28 | 2018-03-26 | Methods of treating neurodegenerative diseases |
Country Status (13)
Country | Link |
---|---|
US (2) | US20200131255A1 (en) |
EP (1) | EP3601337A1 (en) |
JP (2) | JP2020515543A (en) |
KR (1) | KR20190133162A (en) |
CN (2) | CN110494446A (en) |
AU (1) | AU2018244224A1 (en) |
CA (1) | CA3055758A1 (en) |
IL (1) | IL269106A (en) |
MA (1) | MA48996A (en) |
MX (1) | MX2019011423A (en) |
SG (2) | SG11201908326YA (en) |
TW (2) | TW201836640A (en) |
WO (1) | WO2018183175A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20152004A1 (en) | 2013-03-13 | 2016-02-07 | Prothena Biosciences Ltd | IMMUNOTHERAPY TAU |
TWI790642B (en) | 2015-06-05 | 2023-01-21 | 美商建南德克公司 | Anti-tau antibodies and methods of use |
KR102506091B1 (en) | 2016-05-02 | 2023-03-07 | 프로테나 바이오사이언시즈 리미티드 | Tau Immunotherapy |
CU24537B1 (en) | 2016-05-02 | 2021-07-02 | Prothena Biosciences Ltd | MONOCLONAL ANTIBODIES COMPETING TO JOIN HUMAN TAU WITH THE 3D6 ANTIBODY |
KR20230146126A (en) | 2016-12-07 | 2023-10-18 | 제넨테크, 인크. | Anti-tau antibodies and methods of use |
CN110248959B (en) | 2016-12-07 | 2023-06-30 | 基因泰克公司 | anti-TAU antibodies and methods of use |
CN110520440A (en) | 2017-02-17 | 2019-11-29 | 戴纳立制药公司 | Anti- τ antibody and its application method |
AU2018263935A1 (en) | 2017-05-02 | 2019-12-19 | Prothena Biosciences Limited | Antibodies recognizing tau |
JP2022524588A (en) | 2019-03-03 | 2022-05-09 | プロセナ バイオサイエンシーズ リミテッド | Tau recognition antibody |
GB202010652D0 (en) * | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
WO2023028591A1 (en) * | 2021-08-27 | 2023-03-02 | Genentech, Inc. | Methods of treating tau pathologies |
WO2023150483A1 (en) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DE69334255D1 (en) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker for cancer and biosynthetic binding protein for it |
EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
CA2293829C (en) | 1997-06-24 | 2011-06-14 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
BR9813365A (en) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Method for Production and Humanization of a Mouse Monoclonal Antibody |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DK1068241T3 (en) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antibody variants and fragments thereof |
PT1071700E (en) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (en) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polypeptide comprising an Fc region of variant human IgG1 |
PT1914244E (en) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Method of modulating the activity of functional immune molecules |
WO2001025454A2 (en) | 1999-10-04 | 2001-04-12 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
JP4668498B2 (en) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | Method for producing polypeptide |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
CA2785941C (en) | 2000-10-06 | 2017-01-10 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
CN1555411A (en) | 2001-08-03 | 2004-12-15 | ���迨�����\���ɷݹ�˾ | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
JPWO2003085107A1 (en) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | Genome-modified cells |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | Process for producing antibody composition |
JP4628679B2 (en) | 2002-04-09 | 2011-02-09 | 協和発酵キリン株式会社 | Cells in which the activity of a protein involved in GDP-fucose transport is reduced or deleted |
CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
CA2511599A1 (en) | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
WO2005035586A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF a1,6-FUCOSYLTRANSFERASE |
RS55723B1 (en) | 2003-11-05 | 2017-07-31 | Roche Glycart Ag | Antigen binding molecules with increased fc receptor binding affinity and effector function |
WO2005053742A1 (en) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicine containing antibody composition |
RU2386638C2 (en) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Humanised anti-tgf-beta-antibody |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
TWI380996B (en) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | Anti-ox40l antibodies |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
US10118970B2 (en) | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
SI2627672T1 (en) | 2010-10-11 | 2018-10-30 | Biogen International Neuroscience Gmbh | Human anti-tau antibodies |
BR112015003326A2 (en) | 2012-08-16 | 2017-07-04 | Ipierian Inc | methods of treatment of a tauopathy |
PT2935326T (en) | 2012-12-21 | 2020-09-14 | Biogen Ma Inc | Human anti-tau antibodies |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
PE20152004A1 (en) | 2013-03-13 | 2016-02-07 | Prothena Biosciences Ltd | IMMUNOTHERAPY TAU |
TWI734975B (en) | 2014-06-27 | 2021-08-01 | 美商C2N醫療診斷有限責任公司 | Humanized anti-tau antibodies |
TWI790642B (en) * | 2015-06-05 | 2023-01-21 | 美商建南德克公司 | Anti-tau antibodies and methods of use |
-
2018
- 2018-03-26 TW TW107110248A patent/TW201836640A/en unknown
- 2018-03-26 WO PCT/US2018/024300 patent/WO2018183175A1/en unknown
- 2018-03-26 EP EP18720677.6A patent/EP3601337A1/en active Pending
- 2018-03-26 SG SG11201908326Y patent/SG11201908326YA/en unknown
- 2018-03-26 JP JP2019552543A patent/JP2020515543A/en active Pending
- 2018-03-26 TW TW112109248A patent/TW202400231A/en unknown
- 2018-03-26 CA CA3055758A patent/CA3055758A1/en active Pending
- 2018-03-26 CN CN201880021209.2A patent/CN110494446A/en active Pending
- 2018-03-26 CN CN202311141590.5A patent/CN117205311A/en active Pending
- 2018-03-26 MX MX2019011423A patent/MX2019011423A/en unknown
- 2018-03-26 AU AU2018244224A patent/AU2018244224A1/en active Pending
- 2018-03-26 MA MA048996A patent/MA48996A/en unknown
- 2018-03-26 SG SG10201911225WA patent/SG10201911225WA/en unknown
- 2018-03-26 KR KR1020197026447A patent/KR20190133162A/en not_active Application Discontinuation
-
2019
- 2019-09-03 IL IL26910619A patent/IL269106A/en unknown
- 2019-09-19 US US16/576,249 patent/US20200131255A1/en not_active Abandoned
-
2021
- 2021-01-15 US US17/150,201 patent/US20210284720A1/en active Pending
-
2023
- 2023-01-12 JP JP2023002900A patent/JP2023055720A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2019011423A (en) | 2019-11-01 |
SG10201911225WA (en) | 2020-01-30 |
TW201836640A (en) | 2018-10-16 |
RU2019130976A3 (en) | 2021-09-13 |
CA3055758A1 (en) | 2018-10-04 |
US20210284720A1 (en) | 2021-09-16 |
JP2023055720A (en) | 2023-04-18 |
EP3601337A1 (en) | 2020-02-05 |
TW202400231A (en) | 2024-01-01 |
CN117205311A (en) | 2023-12-12 |
US20200131255A1 (en) | 2020-04-30 |
KR20190133162A (en) | 2019-12-02 |
CN110494446A (en) | 2019-11-22 |
MA48996A (en) | 2020-02-05 |
RU2019130976A (en) | 2021-04-28 |
JP2020515543A (en) | 2020-05-28 |
AU2018244224A1 (en) | 2019-09-19 |
WO2018183175A1 (en) | 2018-10-04 |
IL269106A (en) | 2019-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201907846VA (en) | Therapeutic rna | |
SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201408153YA (en) | Prostate-specific membrane antigen antibody drug conjugates | |
SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
SG11201903785TA (en) | Bivalent antibodies masked by coiled coils | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof |